The addition of growth hormone adjuvant therapy to the long down regulation protocol in poor responders undergoing in vitro fertilization: Randomized control trial.

Plain-language guide to PMID 29957401 (2018): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 29957401
Journal: European journal of obstetrics, gynecology, and reproductive biology
Year: 2018
Study type: Randomized Controlled Trial
Authors: Dakhly DMR et al. (6 authors)
DOI: 10.1016/j.ejogrb.2018.06.035
Registered trial: NCT02338206

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To detect the impact of growth hormone (GH) co-treatment to the long down regulation protocol, on the outcomes of IVF/ICSI cycles in poor responders.

Who Took Part

The age groups tagged for this paper are adults, women only.

It included 240 females satisfying the bologna criteria for poor responders.

The enrolled females were randomized into 2 groups: A (long/GH) receiving GH adjuvant therapy to the long protocol and group B (control) receiving the long protocol alone.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

This parallel open label randomized control trial was conducted in a university hospital.

The main outcome measure was the live birth rate (fresh, frozen and cumulative).

What Was Measured

Topics PubMed links to this paper include Birth Rate, Fertilization in Vitro, Human Growth Hormone and Ovulation Induction.

Author keywords: In vitro fertilization, Long down regulation protocol and Poor responders.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.